Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 07 12 2021
accepted: 21 06 2022
entrez: 6 7 2022
pubmed: 7 7 2022
medline: 9 7 2022
Statut: epublish

Résumé

Recurrent parasitic infections may influence the immune response to vaccines. In the Partnership for Research on Ebola VACcinations extended follow-UP and clinical research capacity build-UP (PREVAC-UP) study being undertaken in Mambolo, northern Sierra Leone, participants are being followed up to assess the potential impact of exposure to malaria and/or helminth infections on long-term immune response to two Ebola vaccines. To support the development of the assays that will be used in this evaluation, a parasitological survey was conducted in Mambolo between November 2019 and February 2020. Healthy individuals aged ≥1 year who were resident in Mambolo Chiefdom were selected using a stratified sampling approach and questionnaires were administered to explore their sociodemographic characteristics. Microscopy was used to detect malaria parasites, intestinal helminths and urinary schistosome infections. Rapid blood tests were used to detect infections with Onchocerca volvulus and Wuchereria bancrofti. We estimated the overall prevalence of these infections and used adjusted logistic regression models to explore risk factors for malaria and hookworm infection. Eight hundred and fifteen (815) residents, 50.9% of whom were female were surveyed. Overall, 309 (39.1%) of 791 persons tested for malaria had a positive blood slide; Plasmodium falciparum was the dominant species. Helminth infection was detected in 122 (15.0%) of 815 stool samples including three mixed infections. The helminth infections comprised 102 (12.5%) cases of hookworm, 11 (1.3%) cases of Trichuris trichiura, 10 (1.2%) cases of Schistosoma mansoni and two (0.2%) cases of Ascaris lumbricoides. Being male (OR = 2.01, 95% CI 1.15-3.50) and residing in a non-riverine community (OR = 4.02, 95%CI 2.32-6.98) were the factors associated with hookworm infection. Onchocerca volvulus and Wuchereria bancrofti infections were found in 3.3% and 0.4% of participants respectively. Malaria and hookworm are the most prevalent parasite infections and those most likely to influence long-term immune response to Ebola vaccines among the trial participants.

Identifiants

pubmed: 35793331
doi: 10.1371/journal.pone.0270968
pii: PONE-D-21-38636
pmc: PMC9258822
doi:

Substances chimiques

Ebola Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0270968

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Infect Dis. 2021 Jan;102:422-428
pubmed: 33130207
BMC Med. 2020 Sep 25;18(1):304
pubmed: 32972398
PLoS Negl Trop Dis. 2021 Jun 1;15(6):e0009361
pubmed: 34061838
Parasit Vectors. 2018 Jun 4;11(1):334
pubmed: 29866207
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10178-10183
pubmed: 31036657
Trials. 2021 Jan 23;22(1):86
pubmed: 33485369
Malar J. 2015 Dec 30;14:528
pubmed: 26714465
J Allergy Clin Immunol. 2016 Sep;138(3):666-675
pubmed: 27476889
Parasite Immunol. 2011 Feb;33(2):124-31
pubmed: 21226725
PLoS Negl Trop Dis. 2015 Jan 15;9(1):e0003466
pubmed: 25590337
Lancet. 2018 Sep 1;392(10149):787-790
pubmed: 30104048
PLoS Negl Trop Dis. 2010 Nov 23;4(11):e891
pubmed: 21124881
Lancet. 1978 Jun 24;1(8078):1328-9
pubmed: 78096
Infect Dis Poverty. 2018 Apr 6;7(1):30
pubmed: 29628019
Am J Trop Med Hyg. 2016 Aug 3;95(2):394-400
pubmed: 27273645
Malar J. 2011 Aug 04;10:223
pubmed: 21816032
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
PLoS Negl Trop Dis. 2013 Dec 05;7(12):e2584
pubmed: 24340120
J Infect Dis. 2018 May 18;217(suppl_1):S6-S15
pubmed: 29788345
Malar J. 2013 Jul 01;12:222
pubmed: 23815826

Auteurs

Frank Baiden (F)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Suzanne Fleck (S)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Bailah Leigh (B)

College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.

Philip Ayieko (P)

London School of Hygiene & Tropical Medicine, London, United Kingdom.
Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania.

Daniel Tindanbil (D)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Tuda Otieno (T)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Bolarinde Lawal (B)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Mattu Tehtor (M)

College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.

Maariam Rogers (M)

College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.

Lazarus Odeny (L)

Kenya Medical Research Institute, Centre for Respiratory Diseases Research, Nairobi, Kenya.

Mary H Hodges (MH)

Helen Keller International, Freetown, Sierra Leone.

Mustapha Sonnie (M)

Helen Keller International, Freetown, Sierra Leone.

Mohamed Samai (M)

College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.

David Ishola (D)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Brett Lowe (B)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Deborah Watson-Jones (D)

London School of Hygiene & Tropical Medicine, London, United Kingdom.
Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania.

Brian Greenwood (B)

London School of Hygiene & Tropical Medicine, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH